Doug Drysdale
Doug Drysdale | |
|---|---|
| Born | 8 December 1960 |
| Nationality | British, American |
| Alma mater | University of East Anglia |
| Occupation(s) | Healthcare executive and Entrepreneur |
| Employer | Cybin Inc |
| Known for | Biopharmaceutic |
| Notable work | Former CEO at Alvogen and Pernix Therapeutics |
| Title | CEO at Cybin Inc |
Doug Drysdale (born 8 December 1960), is a British-American pharmaceutics executive and entrepreneur. He is the chairman and CEO of Cybin Inc., a Canadian biopharmaceutical company focused on developing psychedelic therapeutics for mental health disorders, since 2020.[1][2] Prior to Cybin, since 2017, Drysdale was the CEO of Tedor Pharma, a U.S.-based contract development and manufacturing organization.[3]
Drysdale was born in England; he holds a bachelor's degree in Microbial and Molecular Biology from the University of East Anglia, since 1992. Drysdale began his career in 1992 at DuPont Merck Pharmaceutical Company and later held key roles at Elan Corp and Actavis. From 2004 to 2008, he served as Vice President of Mergers and Acquisitions at Actavis.[4] Drysdale later became the founding CEO of Alvogen, leading the company from its inception to an expansion into 35 countries within five years.[5] From 2014 to 2016, he served as chairman and CEO of Pernix Therapeutics.[6] His works have earned him industry recognition, including being named a leading pharmaceutical executive by Pharmaceutical Executive magazine in 2011 and receiving the Ernst & Young Entrepreneur of the Year Award in 2012.[7]
Career
[edit]Drysdale began his healthcare career in 1992 at DuPont Merck Pharmaceutical Company, a joint venture between DuPont Pharmaceutical Company and Merck & Co. that operated from 1991 to 1998. From 1999 to 2002, he served as Director of Business Development at Elan Corp. In 2004, he joined Actavis (now part of Teva Pharmaceuticals) as Vice President of Mergers and Acquisitions (M&A). During his tenure, he completed 15 acquisitions across North America, Europe, and Asia, and raised approximately $3 billion in capital. He served in this role until 2008.[4]
In 2008, Drysdale became the founding CEO of Alvogen, an Icelandic privately owned pharmaceutical company. In this role, he built the company from its inception, achieving $500 million in revenue across 35 countries. In 2011, he was recognized as a leading pharmaceutical executive by Pharmaceutical Executive magazine.[8] Under his leadership, Alvogen completed 16 acquisitions and raised over $4 billion in capital before his departure in 2013.[9]
In 2014, Drysdale became chairman and CEO of Pernix Therapeutics, until 2016. During this time, according to Forbes, the company’s valuation raised from $80 million to $800 million and raised $465 million in capital. He also led the recapitalization of NASDAQ-listed Pernix Therapeutics, raising capital and turning the company from EBITDA negative to EBITDA positive in two quarters.[10] His leadership included launching initiatives like the Pernix Prescriptions Direct program, which improved patient access to treatments.[4][11]
In 2017, Drysdale was appointed CEO of Tedor Pharma, a specialized contract development and manufacturing organization (CDMO) based in Cumberland, Rhode Island. He served for 3 years, during his tenure the Tedor Pharma was named one of the fastest-growing companies in America, making the Inc. 5000 list in 2020.[12] In 2020, Drysdale joined Cybin Inc., an international ethical biopharmaceutical company founded in 2019, Drysdale serves as the CEO, headquartered in Canada. Cybin went public in 2020, uplisting to the NYSE American in 2021, and acquiring Adelia Therapeutics in 2020.[13] Under his leadership, Cybin Inc. achieved major milestones, including receiving FDA Breakthrough Therapy Designation in 2024 for CYB003, a deuterated psilocybin analog for treating major depressive disorder (MDD).[14][15] This designation followed positive results from a Phase 2 study, and the company is planning Phase 3 trials. In 2024, Cybin also advanced CYB004, a deuterated DMT molecule for treating generalized anxiety disorder (GAD).[16]
Recognitions
[edit]- 2011: He was awarded a Pharmaceutical Executive Distinguished Honor for the 2011 International Business Award.[11]
- 2012: He was awarded Ernst & Young Entrepreneur of the Year Award.[7]
References
[edit]- ^ "Cybin Corp Announces Doug Drysdale as Chief Executive Officer". 2020-09-01.
- ^ Lin, Joy (2022-04-19). "Refining Psychedelics into Medicine – An Interview with Doug Drysdale, CEO of Cybin". GeneOnline News. Retrieved 2024-11-22.
- ^ "Tedor Pharma Makes Organizational Changes". Contract Pharma. Retrieved 2024-11-25.
- ^ a b c Hasse, Javier. "Former Actavis Head Of M&A Joins Psychedelics Company As CEO". Forbes. Retrieved 2024-11-22.
- ^ "Houston pharmaceutical company restructures". www.bizjournals.com. Retrieved 2024-11-25.
- ^ "New Pernix CEO's focus will be on expanding team". www.bizjournals.com. Retrieved 2024-11-25.
- ^ a b LLP, Ernst & Young. "Ernst & Young announces winners for the Entrepreneur Of The Year® 2012 New Jersey Award". www.prnewswire.com. Retrieved 2024-11-25.
- ^ "Naples resident named leader in Big Pharma industry". www.naplesnews.com. Retrieved 2024-11-25.
- ^ "FDA Talks Help Cybin Advance Two Psychedelic Drugs Toward Approval". www.clinicalleader.com. Retrieved 2024-11-22.
- ^ Orgambide, Fermin. "A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers - Cybin (AMEX:CYBN)". Benzinga. Retrieved 2024-11-25.
- ^ a b Lawrence, Kelli (2016-03-15). "Lead a Renaissance to Reboot Success". Profile. Retrieved 2024-11-22.
- ^ "10 Psychedelics CEOs To Pay Attention To In 2022". markets.businessinsider.com. 2024-11-22. Retrieved 2024-11-25.
- ^ Buntz, Brian (2022-06-28). "How Cybin aims to maximize the potential of two classical psychedelics". Drug Discovery and Development. Retrieved 2024-11-25.
- ^ O'Brien, Jack (2024-03-27). "Cybin CEO on FDA breakthrough designation for psychedelic drug treating MDD". MM M - Medical Marketing and Media. Retrieved 2024-11-22.
- ^ "Cybin says its psychedelic drug can sustain remission in depression patients". Endpoints News. Retrieved 2024-11-25.
- ^ Dales, Shadd (2023-09-20). "Drysdale Discusses New Investments and Cybin's Plans". The Dales Report. Retrieved 2024-11-22.